A Phase II, Open-label, Non-controlled, Intra-patient Dose-escalation Study to Characterize the Pharmacokinetics After Oral Administration of Eltrombopag in Pediatric Patients With Refractory, Relapsed or Treatment Naive Severe Aplastic Anemia or Recurrent Aplastic Anemia

Trial Profile

A Phase II, Open-label, Non-controlled, Intra-patient Dose-escalation Study to Characterize the Pharmacokinetics After Oral Administration of Eltrombopag in Pediatric Patients With Refractory, Relapsed or Treatment Naive Severe Aplastic Anemia or Recurrent Aplastic Anemia

Recruiting
Phase of Trial: Phase II

Latest Information Update: 14 Aug 2018

At a glance

  • Drugs Eltrombopag (Primary) ; Antithymocyte globulin; Ciclosporin
  • Indications Aplastic anaemia
  • Focus Pharmacokinetics
  • Sponsors Novartis; Novartis Pharma A.G.; Novartis Pharmaceuticals
  • Most Recent Events

    • 17 Jul 2018 Planned End Date changed from 25 Mar 2024 to 1 Apr 2024.
    • 17 Jul 2018 Planned primary completion date changed from 25 Mar 2024 to 1 Apr 2024.
    • 25 Aug 2017 Status changed from not yet recruiting to recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top